Jan Henrik Ter Meulen is a prominent inventor based in Mercer Island, WA (US). He holds a total of nine patents, showcasing his significant contributions to the field of vaccine development and cancer treatment. His work focuses on innovative formulations and delivery systems that enhance immunogenicity and therapeutic efficacy.

Latest Patents

One of his latest patents involves lipid nanoparticle vaccine adjuvants and antigen delivery systems. This invention provides novel lipid nanoparticle (LNP) formulations containing cationic lipids for use as vaccine adjuvants and/or as antigen delivery systems. The objective of this invention is to enhance the humoral and/or cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents. Additionally, the invention identifies physical and chemical properties of the LNP formulations that can be manipulated to improve antigen efficiency and adjuvant tolerability in vivo. Another significant patent application relates to the treatment of cancer, specifically using a pseudotyped lentivirus expressing IL-12 for cancer therapy.

Career Highlights

Throughout his career, Jan has worked with notable companies such as Immune Design Corporation and Merck Sharp & Dohme Corporation. His experience in these organizations has contributed to his expertise in developing innovative solutions in the biomedical field.

Collaborations

Jan has collaborated with esteemed colleagues, including Carlos V Paya Cuenca and Peter Lars Aksel Berglund. These partnerships have further enriched his research and development efforts.

Conclusion

Jan Henrik Ter Meulen's innovative work in vaccine adjuvants and cancer treatment exemplifies his commitment to advancing medical science. His contributions continue to impact the field positively, paving the way for future breakthroughs.

This text is generated by artificial intelligence and may not be accurate.